Who should receive oral antiviral therapy for severe acute respiratory syndrome coronavirus 2 infection in the omicron era? Choose wisely. | Clin Microbiol Infect;29(3): 281-283, 2023 03. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Who should receive oral antiviral therapy for severe acute respiratory syndrome coronavirus 2 infection in the omicron era? Choose wisely.

Weiss, Guenter.

Affiliation

Weiss G; Medical University of Innsbruck, Internal Medicine II, Innsbruck, Austria. Electronic address: guenter.weiss@i-med.ac.at.

Clin Microbiol Infect ; 29(3): 281-283, 2023 03.

Article in En | MEDLINE | ID: mdl-36496153

Subject(s)

COVID-19; Humans; Antiviral Agents

Key words

Molnupiravir; Nirmatrelvir/ritonavir; Omicron; SARS-CoV-2; Vaccination; Viral rebound

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Limits: Humans Language: En Journal: Clin Microbiol Infect Journal subject: DOENCAS TRANSMISSIVEIS / MICROBIOLOGIA Year: 2023 Document type: Article Country of publication: United kingdom

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Limits: Humans Language: En Journal: Clin Microbiol Infect Journal subject: DOENCAS TRANSMISSIVEIS / MICROBIOLOGIA Year: 2023 Document type: Article Country of publication: United kingdom